Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, Phase 3 clinical trial
Psychiatry and Clinical Neurosciences · 2026
DOI: 10.1111/pcn.13917 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2026. Verfasst von Masaki Kato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder, Outcome Assessment, Health Care. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi & Co., Ltd, Japan.
Abstract (Originalsprache)
Aim
To evaluate the efficacy and safety of oral zuranolone for 14 days, compared with placebo, in Japanese patients with major depressive disorder (MDD).
Methods
This multicenter, Phase 3 study was conducted in two parts (70 sites; Japan) including a randomized, double‐blind, placebo‐controlled, parallel‐group part presented herein. Participants aged 18–75 years with the 17‐item Hamilton Rating Scale for Depression (HAMD‐17) total score ≥ 22 were randomized (1:1) ratio to receive either zuranolone (30 mg once daily) or placebo for 14 days with follow‐up on Days 3, 8, and 15 and then weekly for 6 weeks (57 days) thereafter. The primary endpoint was change from baseline in the HAMD‐17 total score at Day 15.
Results
Overall, 412 participants were randomized to receive either zuranolone 30 mg ( n = 207) or placebo ( n = 205). The difference in the least‐squares mean (95% confidence interval [CI]) change from baseline in the HAMD‐17 total score between groups (−1.20; 95% CI: −2.32, −0.08; P = 0.0365) was statistically significant on Day 15. A significant improvement in the HAMD‐17 total score was observed with zuranolone 30 mg during the early treatment period on Days 3 and 8 compared with placebo; however, no significant differences were observed between the groups at later time points, from Day 22 to Day 57. The frequency of adverse events was higher in the zuranolone group (55.1%) than in the placebo group (40.7%); however, no serious adverse events were reported.
Conclusion
Zuranolone improved depressive symptoms on Day 15, compared with placebo, in Japanese patients with MDD. No new safety signals were observed. Clinical Trial Registration jRCT2031210577.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
- Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan.
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
- Shionogi B.V., London, UK.
- Department of Psychiatry, Tokyo Medical University, Tokyo, Japan.
- Sapporo Hanazono Hospital, Hokkaido, Japan.
ORCID-Profile: Masaki Kato, Kazuyuki Nakagome, Hiroki Fukuju, Tomoko Motomiya, Takeshi Inoue
Förderung
- Shionogi & Co., Ltd, Japan
Zitieren
APA
Kato, M., Nakagome, K., Baba, T., Sonoyama, T., Fukuju, H., Shimizu, R., Gomez, J. C., Motomiya, T., & Inoue, T. (2026). Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, Phase 3 clinical trial. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13917
Vancouver
Kato M, Nakagome K, Baba T, Sonoyama T, Fukuju H, Shimizu R, et al. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, Phase 3 clinical trial. Psychiatry and Clinical Neurosciences. 2026. doi:10.1111/pcn.13917
BibTeX
@article{Kato2026,
author = {Kato, Masaki and Nakagome, Kazuyuki and Baba, Takamichi and Sonoyama, Takuhiro and Fukuju, Hiroki and Shimizu, Ryosuke and Gomez, Juan Carlos and Motomiya, Tomoko and Inoue, Takeshi},
title = {Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, Phase 3 clinical trial},
journal = {Psychiatry and Clinical Neurosciences},
year = {2026},
doi = {10.1111/pcn.13917}
}
EUVIMED